托珠单抗治疗结缔组织病相关间质性肺病的研究进展
Research Progress on Tocilizumab in the Treatment of Connective Tissue Disease-Related Interstitial Lung Disease
摘要: 结缔组织病(Connective-Tissue Disease, CTD)常累及全身各个器官，多种CTD如类风湿关节炎(Rheumatoid Arthritis, RA)、系统性硬化症(Systemic Sclerosis, SSc)、系统性红斑狼疮(Systemic Lupus Erythematosus, SLE)等易累及肺脏，严重影响呼吸功能，具有高致死率。目前，临床上多以免疫抑制剂、支持性治疗、抗纤维化治疗及抗氧化治疗为主，但其使用时长、维持和减停标准尚无明确指南，且部分患者疗效不佳。近年来，白介素-6受体(interleukin-6 receptor, IL-6R)拮抗剂托珠单抗(tocilizumab, TCZ)开始尝试应用于多种CTD-ILD患者，但其治疗方案、使用时长还有待探讨。本文将结合近年临床指南和学科进展，对国内外现有文献进行综述，总结TCZ在常见CTD-ILD使用中的研究进展，为临床实践提供参考。
Abstract: Connective-Tissue Disease (CTD) often affects various organs throughout the body. Various CTDs such as Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE) and other diseases can easily affect the lungs, seriously affect respiratory function, and have a high fatality rate. At present, immunosuppressants, supportive treatments, anti-fibrosis treatments and antioxidant treatments are the main clinical treatments. However, there are no clear guidelines for the duration of use, maintenance and reduction standards, and some patients have poor efficacy. In recent years, the interleukin-6 receptor (IL-6R) antagonist tocilizumab (TCZ) has begun to be ap-plied to a variety of CTD-ILD patients, but its treatment options and duration of use have yet to be explored. This article will review the existing literature at home and abroad based on clinical guide-lines and disciplinary progress in recent years, summarize the research progress of TCZ in the use of common CTD-ILD, and provide reference for clinical practice.
文章引用：刘保成, 杨清锐, 麻贞贞, 刘东霞. 托珠单抗治疗结缔组织病相关间质性肺病的研究进展[J]. 临床医学进展, 2024, 14(2): 2814-2820. https://doi.org/10.12677/ACM.2024.142397

参考文献

[1] Cottin, V., Hirani, N.A., Hotchkin, D.L., et al. (2018) Presentation, Diagnosis and Clinical Course of the Spectrum of Progressive-Fibrosing Interstitial Lung Diseases. European Respiratory Review, 27, Article ID: 180076. [Google Scholar] [CrossRef] [PubMed]
[2] Khanna, D., Mittoo, S., Aggarwal, R., et al. (2015) Connective Tissue Disease-Associated Interstitial Lung Diseases (CTD-ILD)—Report from OMERACT CTD-ILD Working Group. The Journal of Rheumatology, 42, 2168-2171. [Google Scholar] [CrossRef] [PubMed]
[3] Jeganathan, N. and Sathananthan, M. (2020) Connective Tissue Dis-ease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment. Lung, 198, 735-759. [Google Scholar] [CrossRef] [PubMed]
[4] Zhang, G., Xu, T., Zhang, H., et al. (2015) [Randomized Con-trol Multi-Center Clinical Study of Mycophenolate Mofetil and Cyclophosphamide in the Treatment of Connective Tissue Disease Related Interstitial Lung Disease]. Chinese Medical Journal, 95, 3641-3645.
[5] Gutiérrez-Adrianzén, O.A., Koutouzov, S., Mota, R.M., Das Chagas Medeiros, M.M., Bach, J.F. and De Holanda Campos, H. (2006) Diagnostic Value of Anti-Nucleosome Antibodies in the Assessment of Disease Activity of Systemic Lupus Erythematosus: A Pro-spective Study Comparing Anti-Nucleosome with Anti-DsDNA Antibodies. The Journal of Rheumatology, 33, 1538-1544.
[6] Ahmed, S. and Handa, R. (2022) Management of Connective Tissue Disease-Related Interstitial Lung Disease. Current Pulmonology Reports, 11, 86-98. [Google Scholar] [CrossRef] [PubMed]
[7] Yoo, H., Hino, T., Hwang, J., et al. (2022) Connective Tissue Disease-Related Interstitial Lung Disease (CTD-ILD) and Interstitial Lung Abnormality (ILA): Evolving Concept of CT Findings, Pathology and Management. European Journal of Radiol-ogy Open, 9, Article ID: 100419. [Google Scholar] [CrossRef] [PubMed]
[8] Schulte, J.J. and Husain, A.N. (2020) Connective Tissue Disease Related Interstitial Lung Disease. Surgical Pathology Clinics, 13, 165-188. [Google Scholar] [CrossRef] [PubMed]
[9] Dale, R.C. (2016) Interleukin-6 Blockade as Rescue Therapy in Autoimmune Encephalitis. Neurotherapeutics, 13, 821-823. [Google Scholar] [CrossRef] [PubMed]
[10] Singh, J.A. (2016) Infections with Biologics in Rheumatoid Arthritis and Related Conditions: A Scoping Review of Serious or Hospitalized Infections in Observational Studies. Current Rheumatology Reports, 18, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[11] Brito, Y., Glassberg, M.K. and Ascherman, D.P. (2017) Rheu-matoid Arthritis-Associated Interstitial Lung Disease: Current Concepts. Current Rheumatology Reports, 19, Article No. 79. [Google Scholar] [CrossRef] [PubMed]
[12] Raimundo, K., Solomon, J.J., Olson, A.L., et al. (2019) Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. The Journal of Rheumatology, 46, 360-369. [Google Scholar] [CrossRef] [PubMed]
[13] Spagnolo, P., Lee, J.S., Sverzellati, N., Rossi, G. and Cottin, V. (2018) The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis & Rheumatology, 70, 1544-1554. [Google Scholar] [CrossRef] [PubMed]
[14] Hyldgaard, C., Hilberg, O., Pedersen, A.B., et al. (2017) A Popula-tion-Based Cohort Study of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Comorbidity and Mortality. An-nals of the Rheumatic Diseases, 76, 1700-1706. [Google Scholar] [CrossRef] [PubMed]
[15] Castelino, F.V. and Varga, J. (2010) Interstitial Lung Dis-ease in Connective Tissue Diseases: Evolving Concepts of Pathogenesis and Management. Arthritis Research & Therapy, 12, Article No. 213. [Google Scholar] [CrossRef] [PubMed]
[16] Carrasco Cubero, C., Chamizo Carmona, E. and Vela Casasempere, P. (2021) Systematic Review of the Impact of Drugs on Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis. Reumatología Clínica (English Edition), 17, 504-513. [Google Scholar] [CrossRef] [PubMed]
[17] Sparks, J.A., He, X., Huang, J., et al. (2019) Rheumatoid Ar-thritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study. Arthritis & Rheumatology, 71, 1472-1482. [Google Scholar] [CrossRef] [PubMed]
[18] Kelly, C.A., Saravanan, V., Nisar, M., et al. (2014) Rheumatoid Arthri-tis-Related Interstitial Lung Disease: Associations, Prognostic Factors and Physiological and Radiological Characteris-tics—A Large Multicentre UK Study. Rheumatology, 53, 1676-1682. [Google Scholar] [CrossRef] [PubMed]
[19] Castellanos-Moreira, R., Rodríguez-García, S.C., Gomara, M.J., et al. (2020) Anti-Carbamylated Proteins Antibody Repertoire in Rheumatoid Arthritis: Evidence of a New Autoantibody Linked to Interstitial Lung Disease. Annals of the Rheumatic Diseases, 79, 587-594. [Google Scholar] [CrossRef] [PubMed]
[20] Juge, P.A., Lee, J.S., Ebstein, E., et al. (2018) MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. The New England Journal of Medicine, 379, 2209-2219. [Google Scholar] [CrossRef] 
[21] Kiely, P., Busby, A.D., Nikiphorou, E., et al. (2019) Is Incident Rheumatoid Arthritis Interstitial Lung Disease Associated with Methotrexate Treatment? Results from a Multi-variate Analysis in the ERAS and ERAN Inception Cohorts. BMJ Open, 9, e028466. [Google Scholar] [CrossRef] [PubMed]
[22] Rojas-Serrano, J., Herrera-Bringas, D., Pérez-Román, D.I., Pérez-Dorame, R., Mateos-Toledo, H. and Mejía, M. (2017) Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Severity of Lung Disease Are Associated to Prognosis. Clinical Rheumatology, 36, 1493-1500. [Google Scholar] [CrossRef] [PubMed]
[23] Vicente-Rabaneda, E.F., Atienza-Mateo, B., Blanco, R., et al. (2021) Efficacy and Safety of Abatacept in Interstitial Lung Disease of Rheumatoid Arthritis: A Systematic Lit-erature Review. Autoimmunity Reviews, 20, Article ID: 102830. [Google Scholar] [CrossRef] [PubMed]
[24] Md Yusof, M.Y., Kabia, A., Darby, M., et al. (2017) Effect of Rituximab on the Progression of Rheumatoid Arthritis-Related Interstitial Lung Disease: 10 Years’ Experience at a Single Centre. Rheumatology, 56, 1348-1357. [Google Scholar] [CrossRef] [PubMed]
[25] Huang, Y., Lin, W., Chen, Z., Wang, Y., Huang, Y. and Tu, S. (2019) Effect of Tumor Necrosis Factor Inhibitors on Interstitial Lung Disease in Rheumatoid Arthritis: Angel or Demon. Drug Design, Development and Therapy, 13, 2111-2125. [Google Scholar] [CrossRef] 
[26] Gan, D., Cheng, W., Ke, L., et al. (2021) Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis. Frontiers in Pharmacology, 12, Article 631891. [Google Scholar] [CrossRef] [PubMed]
[27] Manfredi, A., Sebastiani, M., Cassone, G., Colaci, M., Sandri, G. and Ferri, C. (2018) Tocilizumab for the Treatment of Patients with Rheumatoid Arthritis and Interstitial Lung Diseases: A Case Series. Clinical and Experimental Rheumatology, 36, 342.
[28] Naotatsu Otsuji, K.S., Hajime Arifuku, K.N., Hiroyoshi Watanabe, T.W., Kenya Koyama, H.H. and Fukushima, Y. (2020) Effect of Tocilizumab on Interstitial Lung Disease (ILD) in Patients with Rheumatoid Arthritis (RA). European Respiratory Journal, 56, 747. [Google Scholar] [CrossRef] 
[29] Manfredi, A., Cassone, G., Furini, F., et al. (2020) To-cilizumab Therapy in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicentre Retrospective Study. Internal Medicine Journal, 50, 1085-1090. [Google Scholar] [CrossRef] [PubMed]
[30] 杨书琦, 张慧芳, 宋书林, 余旻. 系统性硬化症发病机制的研究进展[J]. 医学综述, 2018, 24(1): 17-21.
[31] Sánchez-Cano, D., Ortego-Centeno, N., Callejas, J.L., et al. (2018) Interstitial Lung Disease in Systemic Sclerosis: Data from the Spanish Scleroderma Study Group. Rheumatology International, 38, 363-374. [Google Scholar] [CrossRef] [PubMed]
[32] Steele, R., Hudson, M., Lo, E. and Baron, M. (2012) Clinical De-cision Rule to Predict the Presence of Interstitial Lung Disease in Systemic Sclerosis. Arthritis Care & Research, 64, 519-524. [Google Scholar] [CrossRef] [PubMed]
[33] Bergamasco, A., Hartmann, N., Wallace, L. and Verpillat, P. (2019) Epidemiology of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease. Clinical Epidemiology, 11, 257-273. [Google Scholar] [CrossRef] 
[34] Elhai, M., Meune, C., Boubaya, M., et al. (2017) Mapping and Pre-dicting Mortality from Systemic Sclerosis. Annals of the Rheumatic Diseases, 76, 1897-1905. [Google Scholar] [CrossRef] [PubMed]
[35] Ashmore, P., Tikly, M., Wong, M. and Ickinger, C. (2018) Interstitial Lung Disease in South Africans with Systemic Sclerosis. Rheumatology International, 38, 657-662. [Google Scholar] [CrossRef] [PubMed]
[36] Wangkaew, S., Euathrongchit, J., Wattanawittawas, P., Kasitanon, N. and Louthrenoo, W. (2016) Incidence and Predictors of Interstitial Lung Disease (ILD) in Thai Patients with Early Systemic Sclerosis: Inception Cohort Study. Modern Rheumatology, 26, 588-593. [Google Scholar] [CrossRef] [PubMed]
[37] Winstone, T.A., Assayag, D., Wilcox, P.G., et al. (2014) Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease: A Systematic Review. Chest, 146, 422-436. [Google Scholar] [CrossRef] [PubMed]
[38] Wu, W., Jordan, S., Becker, M.O., et al. (2018) Prediction of Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis: The SPAR Model. Annals of the Rheumatic Diseases, 77, 1326-1332. [Google Scholar] [CrossRef] [PubMed]
[39] Scott, L.J. (2017) Tocilizumab: A Review in Rheumatoid Arthritis. Drugs, 77, 1865-1879. [Google Scholar] [CrossRef] [PubMed]
[40] Mihai, C., Dobrota, R., Schröder, M., et al. (2020) COVID-19 in a Patient with Systemic Sclerosis Treated with Tocilizumab for SSc-ILD. Annals of the Rheumatic Diseases, 79, 668-669. [Google Scholar] [CrossRef] [PubMed]
[41] Khanna, D., Lin, C., Furst, D.E., et al. (2022) Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 205, 674-684. [Google Scholar] [CrossRef] 
[42] Kudsi, M., Khalayli, N., Tarcha, R. and Al-Darwish, L. (2023) Tocilizumab in Systemic Sclerosis Treatment: A Case Report. Annals of Medicine & Surgery, 85, 4586-4588. [Google Scholar] [CrossRef] 
[43] Flores-Chávez, A., Kostov, B., Solans, R., et al. (2018) Se-vere, Life-Threatening Phenotype of Primary Sjögren’s Syndrome: Clinical Characterisation and Outcomes in 1580 Pa-tients (GEAS-SS Registry). Clinical and Experimental Rheumatology, 112, 121-129.
[44] Ghosh, A., Das, T., Ghosh, A., Karmakar, P. and Pal, J. (2012) Evaluation of Respiratory Manifestations in Systemic Lupus Erythematosus with Special Reference to Pulmonary Interstitial Involvement. Journal of Indian Medical Association, 110, 109-111.
[45] Zacay, G. and Levy, Y. (2018) Outcomes of Patients with Systemic Sclerosis Treated with Tocilizumab: Case Series and Review of the Literature. Best Practice & Research Clinical Rheumatology, 32, 563-571. [Google Scholar] [CrossRef] [PubMed]
[46] Ma, C.Y., Bikash, S., Li, H., Ding, Q.J. and Fu, P. (2022) Tocili-zumab Therapy for Persistent High-Grade Fever in Systemic Lupus Erythematosus: Two Cases and a Literature Review. Journal of International Medical Research, 50, 1-17. [Google Scholar] [CrossRef] [PubMed]
[47] 陈建锋, 李庆华, 彭建军. 托珠单抗治疗难治性全身型幼年特发性关节炎疗效及安全性[J]. 儿科药学杂志, 2021, 27(11): 8-11.

为你推荐